JoVE Search Results: Age Group

Impact
Papers
Jobs
Conferences

Name	Impact ?	Papers	Institution	Country	Funding
Chayama, Kazuaki	248.6	40	Hiroshima University	Japan	-
Jemal, Ahmedin	211.6	2	Epidemiologist, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.	USA	-
Kumada, Hiromitsu	198.8	48	Toranomon Hospital	Japan	-
Chung, Raymond T	196.8	26	University of Texas Southwestern Medical Center	USA	$29,286,306.00
Rehermann, Barbara	192.9	16	National Institutes of Health	USA	$10,585,476.00
	187.6	16		N/A	-
Narod, S A	185.5	19	Mount Sinai Hospital	Canada	-
Fan, Jia	181.6	27	Fudan University	China	-
Baumert, Thomas F	171.7	19	Inserm, U748, Strasbourg	France	-
Zeuzem, Stefan	164.6	25	J.W. Goethe-University Hospital	Germany	-
Rice, Charles M	162.5	14	The Rockefeller University	USA	$21,689,683.00
Berry, Donald A	159.9	1	University of Vermont	USA	$15,196,711.00
Lemon, Stanley M	157.9	21	The University of North Carolina at Chapel Hill	USA	$25,311,624.00
Bartenschlager, Ralf	153.6	19	Heidelberg University	Germany	-
El-Serag, Hashem B	151.6	20	Baylor College of Medicine	USA	$5,962,295.00
Cheng, Ann-Lii	149.9	23	National Taiwan University Hospital	Taiwan	-
McHutchison, John G	147.3	13	Duke University Medical Center	USA	-
Cacoub, P	145.8	22	Laboratoire de Biologie et ThÃ©rapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C…	France	-
Bukh, Jens	145.6	18	Copenhagen University Hospital	Denmark	-
Pineda, Juan A	144.4	22	Hospital Universitario de Valme	Spain	-
Couch, Fergus J	141.3	7	University of Southern California/Norris Comprehensive Cancer Center	USA	-
Pietschmann, Thomas	139.2	18	Centre for Experimental and Clinical Infection Research	Germany	-
Maehara, Yoshihiko	136.6	35	Aso Iizuka Hospital	Japan	-
Llovet, Josep M	133	13	Mount Sinai School of Medicine	USA	$997,264.00
McKeating, Jane A	129.8	18	University of Birmingham	UK	$216,490.00
Colombo, Massimo	129.8	22	University of Milan	Italy	-
Cristofanilli, M	124.1	3	Dubai Hospital	United Arab Emirates	-
Marcellin, P	123.4	20	INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris	France	-
Pawlotsky, Jean-Michel	122.9	18	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	France	-
Soriano, V	120	23	Hospital Carlos III	Spain	-
Naghavi, Mohsen	114.8	1	University of Washington	USA	-
Dore, Gregory J	110.6	20	The University of New South Wales	Australia	-
McCarthy, Ellen P	110.2	2	Beth Israel Deaconess Medical Center, 1309 Beacon, Office 202, Brookline, MA 02446	USA	-
Buchholz, Thomas A	108.6	5	The University of Texas MD Anderson Cancer Center	USA	-
Perelson, Alan S	107.9	15	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	USA	$5,462,450.00
Thimme, Robert	107.4	14	University of Freiburg	Germany	-
Ploss, Alexander	104.6	8	The Rockefeller University	USA	$625,646.00
He, Xianghuo	104.2	14	Fudan University	China	-
Covey, Anne	101.7	1	Indiana University School of Medicine	USA	-
Sestak, Ivana	99.1	2	Queen Mary University of London	UK	-
Wedemeyer, H	98	20	Hannover Medical School	Germany	-
Sulkowski, Mark S	94.6	9	Johns Hopkins University School of Medicine	USA	-
Liang, T Jake	91	8	National Institutes of Health	USA	$14,690,785.00
Tamimi, Rulla M	90.5	9	Dana-Farber Cancer Institute	USA	$15,347,877.00
Ray, Ranjit	89.2	14	Saint Louis University	USA	$3,735,526.00
Wei, Lin	88.1	17	Hebei Medical University	China	$271,189.00
Nguyen, M H	88	17	Stanford University Medical Center	USA	-
Prins, M	87.9	13	Department of Experimental Virology, Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Center, Amsterdam	Netherlands	-
Kato, Nobuyuki	87.5	20	Okayama University Graduate School of Medicine	Japan	-
Resino, S	86.3	20	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	Spain	-

Name	Institution	Date	Impact	Publication
Jemal, Ahmedin	Epidemiologist, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.	10/01/2013	101.70	CA: a cancer journal for clinicians Breast cancer statistics, 2013. Abstract
Covey, Anne	Indiana University School of Medicine	10/15/2012	101.70	CA: a cancer journal for clinicians Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. Abstract
Cristofanilli, Massimo	The University of Texas M. D. Anderson Cancer Center	10/19/2010	101.70	CA: a cancer journal for clinicians Inflammatory breast cancer: the disease, the biology, the treatment. Abstract
McHutchison, John G	Duke University Medical Center	06/23/2011	53.29	The New England journal of medicine Telaprevir for previously untreated chronic hepatitis C virus infection. Abstract
Berry, Donald A	University of Vermont	05/14/2009	53.29	The New England journal of medicine Adjuvant chemotherapy in older women with early-stage breast cancer. Abstract
Sestak, Ivana	Queen Mary University of London	12/12/2013	38.27	Lancet Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Abstract
Naghavi, Mohsen	University of Washington	09/14/2011	38.27	Lancet Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Abstract
Ploss, Alexander	The Rockefeller University	07/31/2013	36.28	Nature Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Abstract
Ploss, Alexander	The Rockefeller University	06/08/2011	36.28	Nature A genetically humanized mouse model for hepatitis C virus infection. Abstract
Rice, Charles M	The Rockefeller University	01/28/2009	36.28	Nature Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Abstract
Couch, Fergus J	University of Southern California/Norris Comprehensive Cancer Center	10/30/2011	35.53	Nature genetics A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Abstract
Chayama, Kazuaki	Hiroshima University	07/03/2011	35.53	Nature genetics Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Abstract
Tamimi, Rulla M	Harvard School of Public Health	01/30/2011	35.53	Nature genetics Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Abstract
Couch, Fergus J	Mayo Clinic College of Medicine	09/19/2010	35.53	Nature genetics A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Abstract
Sulkowski, Mark S	Johns Hopkins University School of Medicine	07/23/2012	30.02	JAMA Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	02/17/2010	26.56	Cancer cell Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. Abstract
Rice, Charles M	The Rockefeller University	01/31/2010	23.26	Nature biotechnology Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Abstract
		11/17/2010	22.58	The Lancet. Oncology Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Abstract
Sestak, Ivana	Queen Mary University of London	11/17/2010	22.58	The Lancet. Oncology Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Abstract
Cheng, Ann Lii	Beaujon University Hospital	07/06/2009	22.58	The Lancet. Oncology Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Abstract
Rehermann, Barbara	National Institutes of Health	11/24/2013	22.46	Nature medicine Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Abstract
Rice, Charles M	The Rockefeller University	07/09/2013	22.46	Nature medicine Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Abstract
Rehermann, Barbara	National Institutes of Health	07/09/2013	22.46	Nature medicine Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Abstract
Liang, T Jake	National Institutes of Health	05/26/2013	22.46	Nature medicine Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	04/24/2011	22.46	Nature medicine EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Abstract
	Royal Derby Hospital	05/24/2012	21.18	Nature reviews. Microbiology The drugs can work. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	04/29/2009	20.00	Annual review of pathology Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Abstract
He, Xianghuo	Fudan University	03/21/2010	19.48	Nature cell biology Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Abstract
Fan, Jia	Fudan University	11/21/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. Abstract
Buchholz, Thomas A	The University of Texas MD Anderson Cancer Center	11/07/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Improvement in breast cancer outcomes over time: are older women missing out? Abstract
Narod, Steven A	University of Toronto	03/28/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. Abstract
McCarthy, Ellen P	Beth Israel Deaconess Medical Center, 1309 Beacon, Office 202, Brookline, MA 02446	03/14/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Causes of death and relative survival of older women after a breast cancer diagnosis. Abstract
McCarthy, Ellen P	Beth Israel Deaconess Medical Center, 1309 Beacon, Office 202, Brookline, MA 02446	03/22/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. Abstract
Buchholz, Thomas A	the University of Texas MD Anderson Cancer Center	04/29/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Future of cancer incidence in the United States: burdens upon an aging, changing nation. Abstract
Prins, Maria	University of California	04/30/2012	17.39	The Lancet. Infectious diseases Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Abstract
	Royal Derby Hospital	09/12/2013	16.73	Annals of internal medicine Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Abstract
El-Serag, Hashem B	Baylor College of Medicine	01/18/2011	16.73	Annals of internal medicine Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Abstract
Wei, Li	University of Dundee	07/13/2012	16.38	BMJ (Clinical research ed.) Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	08/16/2010	13.85	The Journal of experimental medicine Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. Abstract
Narod, Steven A	The University of Toronto	11/21/2013	13.75	Journal of the National Cancer Institute PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. Abstract
Tamimi, Rulla M	Washington University in St Louis School of Medicine	07/27/2011	13.75	Journal of the National Cancer Institute Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	03/18/2013	13.50	Cell host & microbe HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Abstract
Bartenschlager, Ralf	Heidelberg University	07/23/2012	13.50	Cell host & microbe Dynamic oscillation of translation and stress granule formation mark the cellular response to virus infection. Abstract
Bartenschlager, Ralf	Heidelberg University	01/17/2011	13.50	Cell host & microbe Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Abstract
Chung, Raymond T	Harvard Medical School	03/16/2009	13.50	Cell host & microbe A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Abstract
Chung, Raymond T	Harvard Medical School	09/14/2011	13.10	Annual review of medicine Novel therapies for hepatitis C: insights from the structure of the virus. Abstract
Ploss, Alexander	The Rockefeller University	02/22/2010	13.06	The Journal of clinical investigation New horizons for studying human hepatotropic infections. Abstract
Rehermann, Barbara	National Institutes of Health	07/01/2009	13.06	The Journal of clinical investigation Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. Abstract
Rice, Charles M	The Rockefeller University	02/03/2009	13.06	The Journal of clinical investigation Predicting response to hepatitis C therapy. Abstract
Thimme, Robert	University of Freiburg	01/12/2009	13.06	The Journal of clinical investigation Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. Abstract
Narod, Steven A	Womens College Research Institute	06/26/2012	11.96	Nature reviews. Clinical oncology Breast cancer in young women. Abstract
Bukh, Jens	Copenhagen University Hospital	11/18/2013	11.67	Gastroenterology Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	01/09/2013	11.67	Gastroenterology Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Abstract
Thimme, Robert	University of Freiburg	11/07/2012	11.67	Gastroenterology Factors that determine the antiviral efficacy of HCV-specific CD8(+) T cells ex vivo. Abstract
Rehermann, Barbara	National Institutes of Health	06/13/2012	11.67	Gastroenterology Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Abstract
El-Serag, Hashem B	Baylor College of Medicine	04/27/2012	11.67	Gastroenterology Epidemiology of viral hepatitis and hepatocellular carcinoma. Abstract
Bukh, Jens	Copenhagen University Hospital	04/27/2012	11.67	Gastroenterology Animal models for the study of hepatitis C virus infection and related liver disease. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	04/27/2012	11.67	Gastroenterology New virologic tools for management of chronic hepatitis B and C. Abstract
Sulkowski, Mark S	Johns Hopkins University School of Medicine	04/27/2012	11.67	Gastroenterology Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Abstract
Bartenschlager, Ralf	Heidelberg University	04/19/2012	11.67	Gastroenterology Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	04/10/2012	11.67	Gastroenterology Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	03/27/2012	11.67	Gastroenterology A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Abstract
Liang, T Jake	National Institutes of Health	01/13/2012	11.67	Gastroenterology HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Abstract
McKeating, Jane A	University of Birmingham	12/01/2011	11.67	Gastroenterology Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Abstract
Rehermann, Barbara	National Institutes of Health	07/07/2011	11.67	Gastroenterology Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Abstract
Bartenschlager, Ralf	Heidelberg University	06/13/2011	11.67	Gastroenterology Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Abstract
Bukh, Jens	Copenhagen University Hospital	06/12/2011	11.67	Gastroenterology Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Abstract
Rehermann, Barbara	National Institutes of Health	05/18/2011	11.67	Gastroenterology Delayed induction, not impaired recruitment, of specific CD8⁺ T cells causes the late onset of acute hepatitis C. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	03/24/2011	11.67	Gastroenterology High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Abstract
Llovet, Josep M	Mount Sinai School of Medicine	03/13/2011	11.67	Gastroenterology Targeted therapies for hepatocellular carcinoma. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	02/13/2011	11.67	Gastroenterology MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	02/12/2011	11.67	Gastroenterology Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Abstract
Fan, Jia	Fudan University	02/12/2011	11.67	Gastroenterology CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Abstract
El-Serag, Hashem B	Baylor College of Medicine	12/22/2010	11.67	Gastroenterology Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Abstract
Sulkowski, Mark S	Johns Hopkins University School of Medicine	12/04/2010	11.67	Gastroenterology Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Abstract
Bukh, Jens	Copenhagen University Hospital	11/25/2010	11.67	Gastroenterology Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	11/04/2010	11.67	Gastroenterology Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Abstract
Rehermann, Barbara	National Institutes of Health	10/30/2010	11.67	Gastroenterology Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Abstract
Liang, T Jake	National Institutes of Health	09/17/2010	11.67	Gastroenterology S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Abstract
Maehara, Yoshihiko	Kyushu University	08/12/2010	11.67	Gastroenterology Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Abstract
Sulkowski, Mark S	Johns Hopkins University School of Medicine	06/27/2010	11.67	Gastroenterology Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Abstract
McHutchison, John G	Duke University Medical Center	06/02/2010	11.67	Gastroenterology An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	06/02/2010	11.67	Gastroenterology Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Abstract
McHutchison, John G	Duke University Medical Center	04/24/2010	11.67	Gastroenterology Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Abstract
Chung, Raymond T	Harvard Medical School	03/12/2010	11.67	Gastroenterology Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Abstract
McHutchison, John G	Duke University Medical Center	02/19/2010	11.67	Gastroenterology Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	02/10/2010	11.67	Gastroenterology Glucocorticosteroids increase cell entry by hepatitis C virus. Abstract
Wedemeyer, Heiner	Hannover Medical School	02/02/2010	11.67	Gastroenterology Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	12/16/2009	11.67	Gastroenterology Resistance to direct antiviral agents in patients with hepatitis C virus infection. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	12/04/2009	11.67	Gastroenterology Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Abstract
McKeating, Jane A	University of Birmingham	11/26/2009	11.67	Gastroenterology Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Abstract
Colombo, Massimo	University of Milan	09/18/2009	11.67	Gastroenterology Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Abstract
Rehermann, Barbara	National Institutes of Health	09/10/2009	11.67	Gastroenterology Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	07/24/2009	11.67	Gastroenterology Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Abstract
Liang, T Jake	National Institutes of Health	04/23/2009	11.67	Gastroenterology Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Abstract
Colombo, Massimo	University of Milan	01/29/2009	11.67	Gastroenterology A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Abstract
Colombo, Massimo	University of Milan	01/22/2009	11.67	Gastroenterology Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Abstract
Perelson, Alan S	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	01/01/2009	11.67	Gastroenterology A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Abstract
Thimme, Robert	University of Freiburg	12/13/2008	11.67	Gastroenterology Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Abstract
Perelson, Alan S	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	04/01/2014	11.66	Hepatology (Baltimore, Md.) Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Abstract
McKeating, Jane A	University of Birmingham	02/25/2014	11.66	Hepatology (Baltimore, Md.) Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	02/10/2014	11.66	Hepatology (Baltimore, Md.) Isolate-dependent use of claudins for cell entry by hepatitis C virus. Abstract
McKeating, Jane A	University of Birmingham	12/18/2013	11.66	Hepatology (Baltimore, Md.) Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Abstract
Chung, Raymond T	Harvard Medical School	11/22/2013	11.66	Hepatology (Baltimore, Md.) Human immunodeficiency virus and liver disease forum 2012. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	11/18/2013	11.66	Hepatology (Baltimore, Md.) Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Abstract
Rehermann, Barbara	National Institutes of Health	09/30/2013	11.66	Hepatology (Baltimore, Md.) Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Abstract
Kato, Nobuyuki	Okayama University Graduate School of Medicine	08/19/2013	11.66	Hepatology (Baltimore, Md.) Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Abstract
Bukh, Jens	Copenhagen University Hospital	08/07/2013	11.66	Hepatology (Baltimore, Md.) Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Abstract
El-Serag, Hashem B	Baylor College of Medicine	07/01/2013	11.66	Hepatology (Baltimore, Md.) Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Abstract
El-Serag, Hashem B	Baylor College of Medicine	03/14/2013	11.66	Hepatology (Baltimore, Md.) Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Abstract
Kumada, Hiromitsu	Toranomon Hospital	03/06/2013	11.66	Hepatology (Baltimore, Md.) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Abstract
Kumada, Hiromitsu	Toranomon Hospital	12/05/2012	11.66	Hepatology (Baltimore, Md.) Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Abstract
Rehermann, Barbara	National Institutes of Health	11/19/2012	11.66	Hepatology (Baltimore, Md.) IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Abstract
Rehermann, Barbara	National Institutes of Health	10/14/2012	11.66	Hepatology (Baltimore, Md.) B cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B cell apoptosis. Abstract
Bartenschlager, Ralf	Heidelberg University	10/14/2012	11.66	Hepatology (Baltimore, Md.) Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Abstract
Pineda, Juan A	Hospital Universitario de Valme	09/11/2012	11.66	Hepatology (Baltimore, Md.) Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Abstract
Perelson, Alan S	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	02/15/2012	11.66	Hepatology (Baltimore, Md.) Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Abstract
Kumada, Hiromitsu	Toranomon Hospital	01/30/2012	11.66	Hepatology (Baltimore, Md.) Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Abstract
Colombo, Massimo	University of Milan	01/03/2012	11.66	Hepatology (Baltimore, Md.) Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Abstract
Rice, Charles M	The Rockefeller University	12/06/2011	11.66	Hepatology (Baltimore, Md.) Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Abstract
He, Xianghuo	Fudan University	12/06/2011	11.66	Hepatology (Baltimore, Md.) Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Abstract
Rehermann, Barbara	National Institutes of Health	11/14/2011	11.66	Hepatology (Baltimore, Md.) Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Abstract
Colombo, Massimo	University of Milan	08/19/2011	11.66	Hepatology (Baltimore, Md.) Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Abstract
Liang, T Jake	National Institutes of Health	08/11/2011	11.66	Hepatology (Baltimore, Md.) Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Abstract
Chayama, Kazuaki	Hiroshima University	08/02/2011	11.66	Hepatology (Baltimore, Md.) Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Abstract
Chayama, Kazuaki	Hiroshima University	08/02/2011	11.66	Hepatology (Baltimore, Md.) Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Abstract
Ray, Ranjit	Saint Louis University	07/25/2011	11.66	Hepatology (Baltimore, Md.) Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Abstract
McHutchison, John G	Duke University Medical Center	07/21/2011	11.66	Hepatology (Baltimore, Md.) Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Abstract
Nguyen, Mindie H	Pacific Health Foundation	05/27/2011	11.66	Hepatology (Baltimore, Md.) Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Abstract
Perelson, Alan S	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	05/02/2011	11.66	Hepatology (Baltimore, Md.) Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	04/26/2011	11.66	Hepatology (Baltimore, Md.) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Abstract
Dore, Gregory J	The University of New South Wales	04/11/2011	11.66	Hepatology (Baltimore, Md.) Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Abstract
Chayama, Kazuaki	Hiroshima University	04/11/2011	11.66	Hepatology (Baltimore, Md.) Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. Abstract
McHutchison, John G	Duke University Medical Center	01/21/2011	11.66	Hepatology (Baltimore, Md.) Hepatitis C pharmacogenetics: state of the art in 2010. Abstract
He, Xianghuo	Fudan University	01/03/2011	11.66	Hepatology (Baltimore, Md.) Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Abstract
El-Serag, Hashem B	Baylor College of Medicine	12/13/2010	11.66	Hepatology (Baltimore, Md.) Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Abstract
He, Xianghuo	Fudan University	11/01/2010	11.66	Hepatology (Baltimore, Md.) MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Abstract
Nguyen, Mindie H	Pacific Health Foundation	11/01/2010	11.66	Hepatology (Baltimore, Md.) Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Abstract
Liang, T Jake	National Institutes of Health	10/26/2010	11.66	Hepatology (Baltimore, Md.) Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Abstract
Kumada, Hiromitsu	Toranomon Hospital	08/04/2010	11.66	Hepatology (Baltimore, Md.) Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Abstract
El-Serag, Hashem B	Baylor College of Medicine	07/01/2010	11.66	Hepatology (Baltimore, Md.) Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Abstract
Fan, Jia	Fudan University	07/01/2010	11.66	Hepatology (Baltimore, Md.) CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Abstract
Ray, Ranjit	Saint Louis University	04/30/2010	11.66	Hepatology (Baltimore, Md.) Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokine stimulated acute-phase response. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	04/07/2010	11.66	Hepatology (Baltimore, Md.) Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Abstract
Marcellin, Patrick	Beaujon Hospital	04/07/2010	11.66	Hepatology (Baltimore, Md.) Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	11/05/2009	11.66	Hepatology (Baltimore, Md.) Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Abstract
Pineda, Juan A	Hospital Universitario de Valme	10/05/2009	11.66	Hepatology (Baltimore, Md.) Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Abstract
Chung, Raymond T	Harvard Medical School	10/05/2009	11.66	Hepatology (Baltimore, Md.) Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Abstract
Kato, Nobuyuki	Okayama University Graduate School of Medicine	09/02/2009	11.66	Hepatology (Baltimore, Md.) Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	08/04/2009	11.66	Hepatology (Baltimore, Md.) Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	05/04/2009	11.66	Hepatology (Baltimore, Md.) Seroconversion to hepatitis C virus alternate reading frame protein during acute infection. Abstract
Kumada, Hiromitsu	Toranomon Hospital	03/03/2009	11.66	Hepatology (Baltimore, Md.) Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Abstract
Fan, Jia	Fudan University	02/03/2009	11.66	Hepatology (Baltimore, Md.) Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Abstract
Fan, Jia	Fudan University	02/03/2009	11.66	Hepatology (Baltimore, Md.) Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Abstract
Bukh, Jens	Copenhagen University Hospital	02/03/2009	11.66	Hepatology (Baltimore, Md.) Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Abstract
Rehermann, Barbara	National Institutes of Health	01/05/2009	11.66	Hepatology (Baltimore, Md.) Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Abstract
Bartenschlager, Ralf	Heidelberg University	01/04/2012	10.96	FEMS microbiology reviews Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	05/25/2010	10.35	Trends in molecular medicine Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	02/21/2014	10.33	EMBO molecular medicine Emerging therapies for the treatment of hepatitis C. Abstract
Wedemeyer, H	Hannover Medical School	11/07/2013	10.11	Gut Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Abstract
Chayama, Kazuaki	Hiroshima University	01/15/2013	10.11	Gut Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Abstract
Marcellin, Patrick	Beaujon Hospital	03/02/2012	10.11	Gut Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Abstract
Thimme, Robert	University of Freiburg	08/28/2011	10.11	Gut T cell responses in hepatitis C: the good, the bad and the unconventional. Abstract
Chayama, Kazuaki	Hiroshima University	11/10/2010	10.11	Gut HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Abstract
Marcellin, Patrick	Beaujon Hospital	09/21/2010	10.11	Gut Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	09/14/2010	10.11	Gut Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients. Abstract
Fan, Jia	Fudan University	05/04/2010	10.11	Gut High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Abstract
Marcellin, P	INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris	08/10/2009	10.11	Gut Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Abstract
Pineda, J A	Unidad de Enfermedades Infecciosas. Hospital Universitario de Valme. Avenida de Bellavista, Sevilla	07/21/2009	10.11	Gut Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Abstract
Marcellin, P	INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris	12/11/2008	10.11	Gut Gene expression and hepatitis C virus infection. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	05/03/2010	9.90	Blood Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Abstract
McKeating, Jane A	University of Birmingham	10/06/2008	9.90	Blood Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Abstract
Rice, Charles M	The Rockefeller University	05/20/2013	9.81	Proceedings of the National Academy of Sciences of the United States of America Ultrastructural analysis of hepatitis C virus particles. Abstract
Perelson, Alan S	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	02/19/2013	9.81	Proceedings of the National Academy of Sciences of the United States of America Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	12/17/2012	9.81	Proceedings of the National Academy of Sciences of the United States of America Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication. Abstract
Bukh, Jens	Copenhagen University Hospital	11/14/2012	9.81	Proceedings of the National Academy of Sciences of the United States of America Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Abstract
Bukh, Jens	Copenhagen University Hospital	03/30/2012	9.81	Proceedings of the National Academy of Sciences of the United States of America Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	01/03/2012	9.81	Proceedings of the National Academy of Sciences of the United States of America Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	06/20/2011	9.81	Proceedings of the National Academy of Sciences of the United States of America Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Abstract
Bukh, Jens	Copenhagen University Hospital	03/07/2011	9.81	Proceedings of the National Academy of Sciences of the United States of America MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	09/12/2013	9.26	Journal of hepatology Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. Abstract
Bartenschlager, Ralf	Heidelberg University	08/08/2013	9.26	Journal of hepatology Interferon-stimulated genes and their role in controlling hepatitis C virus. Abstract
Chung, Raymond T	Harvard Medical School	07/02/2013	9.26	Journal of hepatology The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	03/27/2013	9.26	Journal of hepatology Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. Abstract
Colombo, Massimo	University of Milan	03/23/2013	9.26	Journal of hepatology The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. Abstract
Colombo, Massimo	University of Milan	02/26/2013	9.26	Journal of hepatology Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. Abstract
McKeating, Jane A	University of Birmingham	01/23/2013	9.26	Journal of hepatology Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. Abstract
Kumada, Hiromitsu	Toranomon Hospital	11/23/2012	9.26	Journal of hepatology Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	11/05/2012	9.26	Journal of hepatology Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	10/24/2012	9.26	Journal of hepatology Perspectives and challenges of interferon-free therapy for chronic hepatitis C. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	10/04/2012	9.26	Journal of hepatology Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. Abstract
Maehara, Yoshihiko	Kyushu University	08/25/2012	9.26	Journal of hepatology Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. Abstract
He, Xiaoshun	Sun Yat-sen University	07/20/2012	9.26	Journal of hepatology Living donor vs. deceased donor liver transplantation for patients with hepatitis C virus-related diseases. Abstract
Dore, Gregory J	The University of New South Wales	07/14/2012	9.26	Journal of hepatology Case definitions for acute hepatitis C virus infection: a systematic review. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	06/19/2012	9.26	Journal of hepatology Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	05/18/2012	9.26	Journal of hepatology Hepatitis C virus (HCV) protein expression enhances hepatic fibrosis in HCV transgenic mice exposed to a fibrogenic agent. Abstract
Thimme, Robert	University of Freiburg	03/14/2012	9.26	Journal of hepatology Low perforin expression of early differentiated HCV-specific CD8+ T cells limits their hepatotoxic potential. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	02/06/2012	9.26	Journal of hepatology Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Abstract
Perelson, Alan S	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	01/13/2012	9.26	Journal of hepatology Understanding silibinin's modes of action against HCV using viral kinetic modeling. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	01/13/2012	9.26	Journal of hepatology Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Abstract
McKeating, Jane A	University of Birmingham	12/16/2011	9.26	Journal of hepatology A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. Abstract
Pineda, Juan A	Hospital Universitario de Valme	12/13/2011	9.26	Journal of hepatology Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. Abstract
Marcellin, Patrick	Beaujon Hospital	09/25/2011	9.26	Journal of hepatology IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Abstract
Chung, Raymond T	Harvard Medical School	08/31/2011	9.26	Journal of hepatology A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. Abstract
El-Serag, Hashem B	Baylor College of Medicine	07/12/2011	9.26	Journal of hepatology Gaps in the achievement of effectiveness of HCV treatment in national VA practice. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	05/14/2011	9.26	Journal of hepatology A first step towards a mouse model for hepatitis C virus infection containing a human immune system. Abstract
Prins, Maria	University of California	04/13/2011	9.26	Journal of hepatology Hepatitis C in the general population of various ethnic origins living in the Netherlands: should non-Western migrants be screened? Abstract
Llovet, Josep M	Mount Sinai School of Medicine	04/13/2011	9.26	Journal of hepatology Gene-expression signature of vascular invasion in hepatocellular carcinoma. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	03/25/2011	9.26	Journal of hepatology IL28B single nucleotide polymorphisms in the treatment of hepatitis C. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	02/24/2011	9.26	Journal of hepatology Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	02/18/2011	9.26	Journal of hepatology Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Abstract
Chayama, Kazuaki	Hiroshima University	02/04/2011	9.26	Journal of hepatology IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. Abstract
Wedemeyer, Heiner	Hannover Medical School	01/12/2011	9.26	Journal of hepatology Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. Abstract
Chung, Raymond T	Harvard Medical School	12/13/2010	9.26	Journal of hepatology IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. Abstract
Chayama, Kazuaki	Hiroshima University	11/29/2010	9.26	Journal of hepatology ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	11/23/2010	9.26	Journal of hepatology Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Abstract
Chayama, Kazuaki	Hiroshima University	11/18/2010	9.26	Journal of hepatology A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	11/11/2010	9.26	Journal of hepatology Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. Abstract
Thimme, Robert	University of Freiburg	11/09/2010	9.26	Journal of hepatology Potential of immunotherapy for hepatocellular carcinoma. Abstract
Chayama, Kazuaki	Hiroshima University	10/26/2010	9.26	Journal of hepatology Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. Abstract
Dore, Gregory J	The University of New South Wales	10/23/2010	9.26	Journal of hepatology Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. Abstract
Chung, Raymond T	Harvard Medical School	09/29/2010	9.26	Journal of hepatology HIV infection increases HCV-induced hepatocyte apoptosis. Abstract
Chayama, Kazuaki	Hiroshima University	09/19/2010	9.26	Journal of hepatology Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. Abstract
Sulkowski, Mark S	Johns Hopkins University School of Medicine	08/21/2010	9.26	Journal of hepatology Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients. Abstract
Fan, Jia	Fudan University	07/15/2010	9.26	Journal of hepatology PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. Abstract
Chayama, Kazuaki	Hiroshima University	05/31/2010	9.26	Journal of hepatology Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	04/18/2010	9.26	Journal of hepatology Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	03/30/2010	9.26	Journal of hepatology Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	03/15/2010	9.26	Journal of hepatology Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. Abstract
Maehara, Yoshihiko	Kyushu University	03/04/2010	9.26	Journal of hepatology Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. Abstract
Marcellin, Patrick	Beaujon Hospital	03/04/2010	9.26	Journal of hepatology Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	10/23/2009	9.26	Journal of hepatology Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. Abstract
Chayama, Kazuaki	Hiroshima University	09/23/2009	9.26	Journal of hepatology Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	06/12/2009	9.26	Journal of hepatology Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. Abstract
Chung, Raymond T	Harvard Medical School	02/14/2009	9.26	Journal of hepatology Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	12/25/2008	9.26	Journal of hepatology The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. Abstract
Chung, Raymond T	Harvard Medical School	12/03/2008	9.26	Journal of hepatology Treatment failure in hepatitis C: mechanisms of non-response. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	11/05/2008	9.26	Journal of hepatology EWI-2wint--a host cell factor inhibiting hepatitis C virus entry. Abstract
McHutchison, John G	Duke University Medical Center	11/04/2008	9.26	Journal of hepatology Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. Abstract
		05/20/2009	9.23	Human reproduction update Female contraception over 40. Abstract
Pineda, Juan A	Hospital Universitario de Valme	08/14/2013	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Abstract
Prins, Maria	University of California	07/25/2013	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Abstract
Dore, Gregory J	The University of New South Wales	05/31/2013	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Abstract
Pineda, Juan A	Hospital Universitario de Valme	04/10/2013	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Abstract
Soriano, Vincent	Hospital Carlos III	10/22/2012	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver. Abstract
Pineda, Juan A	Hospital Universitario de Valme	09/05/2012	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Abstract
Pineda, Juan A	Hospital Universitario de Valme	09/05/2012	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Abstract
Soriano, Vincent	Hospital Carlos III	10/22/2010	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Abstract
Soriano, Vincent	Hospital Carlos III	10/14/2009	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Abstract
Pineda, Juan A	Hospital Universitario de Valme	09/28/2009	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	01/08/2009	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America New therapies for hepatitis C virus infection. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	05/23/2013	9.13	PLoS pathogens Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	05/02/2013	9.13	PLoS pathogens hepatitis c Virus p7 is critical for capsid assembly and envelopment. Abstract
Bukh, Jens	Copenhagen University Hospital	03/28/2013	9.13	PLoS pathogens Productive homologous and non-homologous recombination of hepatitis C virus in cell culture. Abstract
Bartenschlager, Ralf	Heidelberg University	12/06/2012	9.13	PLoS pathogens Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. Abstract
Thimme, Robert	University of Freiburg	11/29/2012	9.13	PLoS pathogens Rapid antigen processing and presentation of a protective and immunodominant HLA-B*27-restricted hepatitis C virus-specific CD8+ T-cell epitope. Abstract
Perelson, Alan S	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	08/23/2012	9.13	PLoS pathogens Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	07/26/2012	9.13	PLoS pathogens MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. Abstract
Wedemeyer, Heiner	Hannover Medical School	05/19/2011	9.13	PLoS pathogens Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	04/28/2011	9.13	PLoS pathogens Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	07/01/2010	9.13	PLoS pathogens Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. Abstract
Thimme, Robert	University of Freiburg	06/10/2010	9.13	PLoS pathogens Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. Abstract
Bartenschlager, Ralf	Heidelberg University	08/14/2009	9.13	PLoS pathogens Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. Abstract
Bartenschlager, Ralf	Heidelberg University	06/12/2009	9.13	PLoS pathogens Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	04/20/2013	8.73	Annals of the rheumatic diseases Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	09/27/2010	8.73	Annals of the rheumatic diseases Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinaemia vasculitis. Abstract
Cacoub, P	Laboratoire de Biologie et ThÃ©rapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C…	04/23/2008	8.73	Annals of the rheumatic diseases The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Abstract
Cacoub, P	Laboratoire de Biologie et ThÃ©rapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C…	03/28/2008	8.73	Annals of the rheumatic diseases Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Abstract
He, Xianghuo	Fudan University	12/03/2013	8.19	Cell research Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Abstract
Dore, Gregory J	The University of New South Wales	07/02/2013	8.10	Nature reviews. Gastroenterology & hepatology Epidemiology and natural history of HCV infection. Abstract
Chayama, Kazuaki	Hiroshima University	05/29/2012	8.10	Nature reviews. Gastroenterology & hepatology Genetics of IL28B and HCV--response to infection and treatment. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	04/05/2011	8.10	Nature reviews. Gastroenterology & hepatology A new standard of care for the treatment of chronic HCV infection. Abstract
Dore, Gregory J	The University of New South Wales	03/22/2011	8.10	Nature reviews. Gastroenterology & hepatology Treatment of acute HCV infection. Abstract
Marcellin, Patrick	Beaujon Hospital	08/28/2009	8.10	Nature reviews. Gastroenterology & hepatology Hepatitis C: The role of new interferons in the era of STAT-C. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	06/01/2011	7.87	Arthritis and rheumatism Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	12/16/2009	7.87	Arthritis and rheumatism Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	08/11/2009	7.87	Arthritis and rheumatism Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Abstract
Fan, Jia	Fudan University	06/18/2012	7.86	Cancer research CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Abstract
Couch, Fergus J	Mayo Clinic College of Medicine	02/13/2012	7.86	Cancer research 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Abstract
Couch, Fergus J	Mayo Clinic College of Medicine	08/15/2011	7.86	Cancer research Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	06/08/2010	7.86	Cancer research Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest. Abstract
Ray, Ranjit	Saint Louis University	08/04/2011	7.80	Science translational medicine Progress toward development of a hepatitis C vaccine with broad shoulders. Abstract
Perelson, Alan S	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	05/06/2010	7.80	Science translational medicine Rapid emergence of protease inhibitor resistance in hepatitis C virus. Abstract
Rice, Charles M	The Rockefeller University	04/07/2010	7.80	Science translational medicine Antisense gets a grip on miR-122 in chimpanzees. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	07/18/2012	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	05/23/2012	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Abstract
Fan, Jia	Fudan University	08/08/2011	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	09/30/2010	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	08/16/2010	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research New strategies in hepatocellular carcinoma: genomic prognostic markers. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	09/08/2009	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Abstract
Fan, Jia	Fudan University	08/25/2009	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Abstract
Fan, Jia	Fudan University	10/01/2011	7.45	Autophagy Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Abstract
Fan, Jia	Fudan University	04/19/2009	7.45	Autophagy Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma. Abstract
Rice, Charles M	The Rockefeller University	10/16/2009	7.36	EMBO reports Towards a small animal model for hepatitis C. Abstract
Chayama, Kazuaki	Hiroshima University	07/30/2013	7.28	The American journal of gastroenterology A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing. Abstract
Kumada, Hiromitsu	Toranomon Hospital	10/18/2011	7.28	The American journal of gastroenterology Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Abstract
El-Serag, Hashem B	Baylor College of Medicine	11/09/2010	7.28	The American journal of gastroenterology Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Abstract
McHutchison, John G	Duke University Medical Center	10/05/2010	7.28	The American journal of gastroenterology IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Abstract
Nguyen, Mindie H	Pacific Health Foundation	11/10/2009	7.28	The American journal of gastroenterology Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. Abstract
McKeating, Jane A	University of Birmingham	03/06/2012	7.20	Reviews in medical virology Hepatitis C virus entry: beyond receptors. Abstract
Chung, Raymond T	Harvard Medical School	11/12/2013	7.05	Seminars in liver disease HCV and host lipids: an intimate connection. Abstract
Colombo, Massimo	University of Milan	03/01/2013	7.05	Seminars in liver disease Shaping the future management of hepatocellular carcinoma. Abstract
Soriano, Vincent	Hospital Carlos III	07/03/2012	7.05	Seminars in liver disease Management and treatment of chronic hepatitis C in HIV patients. Abstract
Dore, Gregory J	The University of New South Wales	12/21/2011	7.05	Seminars in liver disease What is killing people with hepatitis C virus infection? Abstract
Chung, Raymond T	Harvard Medical School	12/21/2011	7.05	Seminars in liver disease The impact of human gene polymorphisms on HCV infection and disease outcome. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	10/19/2010	7.05	Seminars in liver disease Hepatitis A and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Abstract
Bartenschlager, Ralf	Heidelberg University	10/19/2010	7.05	Seminars in liver disease New insights into structure and replication of the hepatitis C virus and clinical implications. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	09/15/2009	6.86	Current opinion in pharmacology Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	11/09/2013	6.62	Autoimmunity reviews Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. Abstract
Nguyen, Mindie H	Pacific Health Foundation	12/17/2013	6.53	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for End-stage Liver Disease score. Abstract
El-Serag, Hashem B	Baylor College of Medicine	08/23/2013	6.53	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Abstract
Chung, Raymond T	Harvard Medical School	07/18/2013	6.53	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Direct-acting antiviral agents and the path to interferon independence. Abstract
El-Serag, Hashem B	Baylor College of Medicine	10/04/2012	6.53	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Abstract
Nguyen, Mindie H	Pacific Health Foundation	08/16/2012	6.53	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Abstract
El-Serag, Hashem B	Baylor College of Medicine	12/07/2011	6.53	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Abstract
El-Serag, Hashem B	Baylor College of Medicine	08/04/2011	6.53	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Abstract
Prins, Maria	University of California	05/20/2011	6.53	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. Abstract
Cristofanilli, M	Dubai Hospital	07/05/2010	6.43	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Abstract
Wedemeyer, Heiner	Hannover Medical School	10/23/2013	6.41	The Journal of infectious diseases Compromised function of natural killer cells in acute and chronic viral hepatitis. Abstract
Rehermann, Barbara	National Institutes of Health	06/24/2013	6.41	The Journal of infectious diseases Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. Abstract
Chung, Raymond T	Harvard Medical School	02/07/2013	6.41	The Journal of infectious diseases Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. Abstract
Dore, Gregory J	The University of New South Wales	02/07/2013	6.41	The Journal of infectious diseases Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. Abstract
Sulkowski, Mark S	Johns Hopkins University School of Medicine	02/07/2013	6.41	The Journal of infectious diseases Current management of hepatitis C virus infection in patients with HIV co-infection. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	01/18/2013	6.41	The Journal of infectious diseases Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization. Abstract
Dore, Gregory J	The University of New South Wales	09/04/2012	6.41	The Journal of infectious diseases Impaired hepatitis C virus (HCV)-specific interferon-γ responses in individuals with HIV who acquire HCV infection: correlation with CD4(+) T-cell counts. Abstract
Wedemeyer, Heiner	Hannover Medical School	03/29/2012	6.41	The Journal of infectious diseases Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. Abstract
Thimme, Robert	University of Freiburg	02/20/2012	6.41	The Journal of infectious diseases Differential antigen specificity of hepatitis C virus-specific interleukin 17- and interferon γ-producing CD8(+) T cells during chronic infection. Abstract
Rehermann, Barbara	National Institutes of Health	01/31/2012	6.41	The Journal of infectious diseases Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. Abstract
Soriano, Vincent	Hospital Carlos III	12/09/2011	6.41	The Journal of infectious diseases Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. Abstract
Zeuzem, Stefan	J.W. Goethe-University Hospital	07/27/2011	6.41	The Journal of infectious diseases Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. Abstract
Chung, Raymond T	Harvard Medical School	07/27/2011	6.41	The Journal of infectious diseases Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase. Abstract
Kumada, Hiromitsu	Toranomon Hospital	06/01/2011	6.41	The Journal of infectious diseases IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. Abstract
Soriano, Vincent	Hospital Carlos III	05/19/2011	6.41	The Journal of infectious diseases Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	10/04/2010	6.41	The Journal of infectious diseases Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. Abstract
Maehara, Y	Kyushu University	06/07/2011	6.39	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons The impact of IL28B genetic variants on recurrent hepatitis C in liver transplantation: significant lessons from a dual graft case. Abstract
Nguyen, M H	Stanford University Medical Center	03/16/2009	6.39	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Abstract
Pawlotsky, J-M	Institut National de la Santé et de la Recherche Médicale (INSERM), U955, Institut Mondor de Recherche Biomédicale, Créteil	10/29/2012	6.37	Oncogene Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Abstract
Lemon, S M	The University of North Carolina at Chapel Hill	01/24/2011	6.37	Oncogene Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Abstract
Chung, R T	Harvard Medical School	03/15/2010	6.37	Oncogene Viral hepatocarcinogenesis. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	08/07/2012	6.27	Seminars in immunopathology Innate immune responses in hepatitis C virus infection. Abstract
Colombo, Massimo	University of Milan	07/22/2012	6.27	Seminars in immunopathology Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Abstract
Pineda, Juan A	Hospital Universitario de Valme	01/13/2014	6.25	AIDS (London, England) HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. Abstract
Pineda, Juan A	Hospital Universitario de Valme	01/03/2014	6.25	AIDS (London, England) Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. Abstract
Pineda, Juan A	Hospital Universitario de Valme	10/07/2013	6.25	AIDS (London, England) Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. Abstract
Soriano, Vicente	Hospital Universitario de Valme	08/01/2013	6.25	AIDS (London, England) Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	07/01/2013	6.25	AIDS (London, England) HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. Abstract
	Royal Derby Hospital	05/31/2013	6.25	AIDS (London, England) Hepatitis-B virus infection predicts mortality of HIV and hepatitis C virus coinfected patients. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	12/17/2012	6.25	AIDS (London, England) Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. Abstract
Prins, Maria	University of California	10/25/2011	6.25	AIDS (London, England) Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	08/04/2011	6.25	AIDS (London, England) European mitochondrial DNA haplogroups and liver fibrosis in HIV and hepatitis C virus coinfected patients. Abstract
Prins, Maria	University of California	05/03/2011	6.25	AIDS (London, England) The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. Abstract
Soriano, Vincent	Hospital Carlos III	05/03/2011	6.25	AIDS (London, England) Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse. Abstract
Soriano, Vincent	Hospital Carlos III	03/18/2011	6.25	AIDS (London, England) Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	08/03/2010	6.25	AIDS (London, England) Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. Abstract
Soriano, Vincent	Hospital Carlos III	04/27/2010	6.25	AIDS (London, England) Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Abstract
Sulkowski, Mark S	Johns Hopkins University School of Medicine	03/17/2010	6.25	AIDS (London, England) Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons. Abstract
Prins, Maria	University of California	07/23/2009	6.25	AIDS (London, England) Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. Abstract
Prins, M	Department of Experimental Virology, Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Center, Amsterdam	04/15/2010	6.15	Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin Evaluation of a risk assessment questionnaire to assist hepatitis C screening in the general population. Abstract
Narod, Steven A	University of Toronto	07/19/2011	6.05	Cancer treatment reviews Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	01/08/2013	6.04	BMC medicine Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. Abstract
Nguyen, M H	Stanford University Medical Center	11/19/2013	5.48	Alimentary pharmacology & therapeutics Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Abstract
Wedemeyer, H	Hannover Medical School	11/10/2013	5.48	Alimentary pharmacology & therapeutics Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Abstract
El-Serag, H B	Clinical Epidemiology and Outcomes Program	05/26/2013	5.48	Alimentary pharmacology & therapeutics The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Abstract
Nguyen, M H	Stanford University Medical Center	04/05/2013	5.48	Alimentary pharmacology & therapeutics Systematic review: Asian patients with chronic hepatitis C infection. Abstract
Nguyen, M H	Stanford University Medical Center	05/29/2011	5.48	Alimentary pharmacology & therapeutics Systematic review: epidemiology of hepatitis C genotype 6 and its management. Abstract
Cacoub, P	Laboratoire de Biologie et ThÃ©rapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C…	03/09/2009	5.48	Alimentary pharmacology & therapeutics Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Abstract
McKeating, J A	University of Birmingham	11/20/2012	5.46	Cellular microbiology Hepatoma polarization limits CD81 and hepatitis C virus dynamics. Abstract
Fan, Jia	Fudan University	08/07/2012	5.44	International journal of cancer. Journal international du cancer Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Abstract
Kato, Naoya	Shandong University	12/21/2011	5.44	International journal of cancer. Journal international du cancer Type 2 diabetes and hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	11/19/2011	5.44	International journal of cancer. Journal international du cancer The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Abstract
Fan, Jia	Fudan University	04/20/2011	5.44	International journal of cancer. Journal international du cancer Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Abstract
Chung, Raymond T	Harvard Medical School	07/03/2012	5.44	The Journal of pediatrics Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	10/25/2012	5.43	American journal of kidney diseases : the official journal of the National Kidney Foundation Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Abstract
Kumada, Hiromitsu	Toranomon Hospital	04/20/2009	5.43	The American journal of medicine Necessities of interferon therapy in elderly patients with chronic hepatitis C. Abstract
Ray, Ranjit	Saint Louis University	12/18/2013	5.40	Journal of virology Hepatitis C virus impairs natural killer cell-mediated augmentation of complement synthesis. Abstract
Bukh, Jens	Copenhagen University Hospital	11/20/2013	5.40	Journal of virology Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	10/30/2013	5.40	Journal of virology Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	10/02/2013	5.40	Journal of virology Characterization of hepatitis C virus intra- and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment. Abstract
Bartenschlager, Ralf	Heidelberg University	07/24/2013	5.40	Journal of virology Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	07/17/2013	5.40	Journal of virology Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. Abstract
Rice, Charles M	The Rockefeller University	05/22/2013	5.40	Journal of virology Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. Abstract
Ray, Ranjit	Saint Louis University	05/08/2013	5.40	Journal of virology Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. Abstract
Ray, Ranjit	Saint Louis University	03/13/2013	5.40	Journal of virology Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. Abstract
Rice, Charles M	The Rockefeller University	02/13/2013	5.40	Journal of virology Genetic and functional characterization of the N-terminal region of the hepatitis C virus NS2 protein. Abstract
Rehermann, Barbara	National Institutes of Health	02/06/2013	5.40	Journal of virology The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	01/30/2013	5.40	Journal of virology Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	11/21/2012	5.40	Journal of virology Subcellular localization and function of an epitope-tagged p7 viroporin in hepatitis C virus-producing cells. Abstract
Bukh, Jens	Copenhagen University Hospital	11/14/2012	5.40	Journal of virology Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry. Abstract
Ray, Ranjit	Saint Louis University	10/03/2012	5.40	Journal of virology Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	08/15/2012	5.40	Journal of virology Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. Abstract
Ray, Ranjit	Saint Louis University	07/03/2012	5.40	Journal of virology Hepatitis C virus-mediated inhibition of cathepsin S increases invariant-chain expression on hepatocyte surface. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	04/24/2012	5.40	Journal of virology Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus. Abstract
Ray, Ranjit	Saint Louis University	03/28/2012	5.40	Journal of virology Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. Abstract
McKeating, Jane A	University of Birmingham	02/08/2012	5.40	Journal of virology Hepatitis C virus induces CD81 and claudin-1 endocytosis. Abstract
Ray, Ranjit	Saint Louis University	12/14/2011	5.40	Journal of virology Hepatitis C virus proteins inhibit C3 complement production. Abstract
Bartenschlager, Ralf	Heidelberg University	05/04/2011	5.40	Journal of virology NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. Abstract
Kato, Nobuyuki	Okayama University Graduate School of Medicine	05/04/2011	5.40	Journal of virology Hepatitis C virus hijacks P-body and stress granule components around lipid droplets. Abstract
Thimme, Robert	University of Freiburg	03/02/2011	5.40	Journal of virology Immunodominance of HLA-A2-restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency. Abstract
Ray, Ranjit	Saint Louis University	02/23/2011	5.40	Journal of virology Transcriptional repression of C4 complement by hepatitis C virus proteins. Abstract
Bukh, Jens	Copenhagen University Hospital	12/22/2010	5.40	Journal of virology Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. Abstract
Bukh, Jens	Copenhagen University Hospital	12/01/2010	5.40	Journal of virology Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. Abstract
McKeating, Jane A	University of Birmingham	10/20/2010	5.40	Journal of virology Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	04/28/2010	5.40	Journal of virology Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	04/14/2010	5.40	Journal of virology DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not for internal ribosome entry site-directed translation. Abstract
Chung, Raymond T	Harvard Medical School	04/07/2010	5.40	Journal of virology Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. Abstract
Ray, Ranjit	Saint Louis University	03/31/2010	5.40	Journal of virology Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. Abstract
Bukh, Jens	Copenhagen University Hospital	03/03/2010	5.40	Journal of virology Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. Abstract
Liang, T Jake	National Institutes of Health	01/20/2010	5.40	Journal of virology Novel function of CD81 in controlling hepatitis C virus replication. Abstract
Rice, Charles M	The Rockefeller University	12/09/2009	5.40	Journal of virology Genetic analysis of the carboxy-terminal region of the hepatitis C virus core protein. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	11/04/2009	5.40	Journal of virology Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. Abstract
Rice, Charles M	The Rockefeller University	10/07/2009	5.40	Journal of virology Determinants of the hepatitis C virus nonstructural protein 2 protease domain required for production of infectious virus. Abstract
McKeating, Jane A	University of Birmingham	09/23/2009	5.40	Journal of virology Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. Abstract
Bartenschlager, Ralf	Heidelberg University	09/09/2009	5.40	Journal of virology Role of RNA structures in genome terminal sequences of the hepatitis C virus for replication and assembly. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	09/02/2009	5.40	Journal of virology Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. Abstract
Ray, Ranjit	Saint Louis University	07/15/2009	5.40	Journal of virology Hepatitis C virus core protein and cellular protein HAX-1 promote 5-fluorouracil-mediated hepatocyte growth inhibition. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	05/20/2009	5.40	Journal of virology Impaired replication of hepatitis C virus containing mutations in a conserved NS5B retinoblastoma protein-binding motif. Abstract
McKeating, Jane A	University of Birmingham	04/08/2009	5.40	Journal of virology Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. Abstract
Kato, Nobuyuki	Okayama University Graduate School of Medicine	12/24/2008	5.40	Journal of virology Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	05/02/2013	5.27	Expert opinion on investigational drugs Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection. Abstract
Bartenschlager, Ralf	Heidelberg University	11/21/2013	5.25	Journal of medicinal chemistry On the history of hepatitis C virus cell culture systems. Abstract
Couch, Fergus J	University of Southern California/Norris Comprehensive Cancer Center	01/07/2012	5.25	Breast cancer research : BCR No evidence for association of inherited variation in genes involved in mitosis and percent mammographic density. Abstract
Perelson, Alan S	Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545	03/14/2013	5.22	PLoS computational biology Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. Abstract
Fan, Jia	Fudan University	03/05/2013	5.11	Journal of proteome research Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma. Abstract
Pineda, Juan A	Hospital Universitario de Valme	12/12/2012	5.07	The Journal of antimicrobial chemotherapy A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	01/31/2012	5.07	The Journal of antimicrobial chemotherapy Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	01/14/2011	5.07	The Journal of antimicrobial chemotherapy Sustained virological response to interferon-α plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients. Abstract
Soriano, Vincent	Hospital Carlos III	12/23/2009	5.07	The Journal of antimicrobial chemotherapy Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	12/16/2009	5.07	The Journal of antimicrobial chemotherapy Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients. Abstract
Fan, J	Fudan University	09/03/2013	5.04	British journal of cancer Prognostic value of peritumoral heat-shock factor-1 in patients receiving resection of hepatocellular carcinoma. Abstract
Cheng, A-L	National Taiwan University Hospital	12/20/2012	5.04	British journal of cancer Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Abstract
Cheng, A-L	National Taiwan University Hospital	10/11/2012	5.04	British journal of cancer Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Abstract
Narod, S A	University of Toronto	05/15/2012	5.04	British journal of cancer Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Abstract
He, X	Shanghai Jiao Tong University School of Medicine	11/23/2010	5.04	British journal of cancer The role of microRNAs in liver cancer progression. Abstract
Cheng, A-L	National Taiwan University Hospital	02/16/2010	5.04	British journal of cancer Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Abstract
Narod, S A	University of Toronto	04/29/2009	5.04	British journal of cancer Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Abstract
Narod, S A	University of Toronto	12/16/2008	5.04	British journal of cancer Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	05/22/2013	4.93	RNA biology miR-122 and the Hepatitis C RNA genome: more than just stability. Abstract
Bartenschlager, Ralf	Heidelberg University	03/01/2011	4.93	RNA biology Hepatitis C virus and host cell lipids: an intimate connection. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	03/06/2013	4.93	Current topics in microbiology and immunology Cell culture systems for hepatitis C virus. Abstract
Ploss, Alexander	The Rockefeller University	03/06/2013	4.93	Current topics in microbiology and immunology Animal models for hepatitis C. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	03/06/2013	4.93	Current topics in microbiology and immunology Hepatitis C virus entry. Abstract
Rice, Charles M	The Rockefeller University	03/06/2013	4.93	Current topics in microbiology and immunology Innate immune responses to hepatitis C virus. Abstract
Thimme, Robert	University of Freiburg	03/06/2013	4.93	Current topics in microbiology and immunology Adaptive immune responses in hepatitis C virus infection. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	03/06/2013	4.93	Current topics in microbiology and immunology Liver injury and disease pathogenesis in chronic hepatitis C. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	03/06/2013	4.93	Current topics in microbiology and immunology Treatment of chronic hepatitis C: current and future. Abstract
Cacoub, P	Laboratoire de Biologie et ThÃ©rapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C…	10/27/2010	4.85	Arthritis care & research Hepatitis C virus-associated polyarteritis nodosa. Abstract
Liang, T Jake	National Institutes of Health	11/25/2013	4.84	Antimicrobial agents and chemotherapy Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. Abstract
Chung, Raymond T	Harvard Medical School	11/22/2010	4.77	The Journal of biological chemistry HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. Abstract
Bartenschlager, Ralf	Heidelberg University	11/05/2010	4.77	The Journal of biological chemistry Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. Abstract
McKeating, Jane A	University of Birmingham	04/07/2010	4.77	The Journal of biological chemistry Claudin association with CD81 defines hepatitis C virus entry. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	10/06/2009	4.77	The Journal of biological chemistry Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. Abstract
Cristofanilli, Massimo	The University of Texas M. D. Anderson Cancer Center	11/29/2010	4.77	Cancer Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	09/27/2010	4.77	Cancer Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Abstract
Kumada, Hiromitsu	Toranomon Hospital	01/26/2009	4.77	Cancer High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Abstract
Soriano, Vicente	Hospital Universitario de Valme	10/14/2011	4.75	Current opinion in HIV and AIDS Host genetics. Abstract
		02/23/2011	4.73	Obstetrics and gynecology Committee Opinion No. 482: Colonoscopy and colorectal cancer screening strategies. Abstract
		07/28/2010	4.73	Obstetrics and gynecology ACOG Committee Opinion No. 463: Cervical cancer in adolescents: screening, evaluation, and management. Abstract
		03/23/2009	4.73	Obstetrics and gynecology ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Abstract
Maehara, Y	Kyushu University	12/24/2010	4.61	The British journal of surgery Prognostic importance of the gross classification of hepatocellular carcinoma in living donor-related liver transplantation. Abstract
Buchholz, Thomas A	the University of Texas MD Anderson Cancer Center	08/20/2009	4.55	Journal of the American College of Surgeons Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. Abstract
Tamimi, Rulla M	Washington University in St Louis School of Medicine	10/18/2013	4.43	Breast cancer research and treatment Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? Abstract
Tamimi, Rulla M	Harvard School of Public Health	04/23/2013	4.43	Breast cancer research and treatment Radial scars and subsequent breast cancer risk: results from the Nurses' Health Studies. Abstract
Tamimi, Rulla M	Harvard School of Public Health	10/21/2012	4.43	Breast cancer research and treatment Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies. Abstract
Tamimi, Rulla M	Harvard School of Public Health	05/24/2012	4.43	Breast cancer research and treatment Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease. Abstract
Tamimi, Rulla M	Harvard School of Public Health	07/05/2011	4.43	Breast cancer research and treatment COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Abstract
Narod, Steven A	University of Toronto	04/01/2011	4.43	Breast cancer research and treatment The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Abstract
Narod, Steven A	University of Toronto	01/09/2011	4.43	Breast cancer research and treatment Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Abstract
Narod, Steven A	Womens College Research Institute	01/04/2011	4.43	Breast cancer research and treatment Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening. Abstract
	Sichuan University	08/12/2009	4.43	Breast cancer research and treatment Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism. Abstract
Couch, Fergus J	Mayo Clinic College of Medicine	12/11/2008	4.43	Breast cancer research and treatment No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	11/15/2013	4.43	Journal of acquired immune deficiency syndromes (1999) Prediction of hepatic fibrosis in patients coinfected with HIV and hepatitis C virus based on genetic markers. Abstract
Soriano, Vincent	Hospital Carlos III	03/15/2010	4.43	Journal of acquired immune deficiency syndromes (1999) Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse. Abstract
Prins, Maria	University of California	02/08/2012	4.31	Addiction (Abingdon, England) The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Abstract
Cacoub, Patrice	Groupe Hospitalier PitiÃ©-SalpÃ©triÃ¨re	11/30/2012	4.31	Current opinion in rheumatology Cryoglobulinemia vasculitis: an update. Abstract
McKeating, J A	University of Birmingham	10/21/2013	4.30	Antiviral research Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission. Abstract
Wei, Lai	Peking University Hepatology Institute	02/16/2013	4.30	Antiviral research BST2/Tetherin inhibits hepatitis C virus production in human hepatoma cells. Abstract
Chung, Raymond T	Harvard Medical School	12/10/2012	4.30	Antiviral research SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication. Abstract
Pineda, Juan A	Hospital Universitario de Valme	06/29/2012	4.30	Antiviral research HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. Abstract
Pineda, Juan Antonio	Hospital Universitario de Valme	06/07/2012	4.30	Antiviral research No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	12/15/2010	4.30	Antiviral research Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	07/14/2010	4.30	Antiviral research miR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes. Abstract
Rice, Charles M	The Rockefeller University	02/25/2010	4.30	Antiviral research Creation and characterization of a cell-death reporter cell line for hepatitis C virus infection. Abstract
Wei, Lin	Hebei Medical University	07/29/2009	4.30	Antiviral research A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Abstract
Kato, Nobuyuki	Okayama University Graduate School of Medicine	02/06/2009	4.30	Antiviral research Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	07/18/2013	4.24	Cancer letters Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies? Abstract
He, Xianghuo	Fudan University	08/22/2011	4.24	Cancer letters Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	06/23/2009	4.21	Journal of innate immunity Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. Abstract
Llovet, Josep M	Mount Sinai School of Medicine	04/23/2009	4.19	Current opinion in gastroenterology Pathogenesis of hepatocellular carcinoma and molecular therapies. Abstract
Maehara, Yoshihiko	Kyushu University	12/28/2011	4.17	Annals of surgical oncology Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. Abstract
Fan, Jia	Fudan University	07/27/2011	4.17	Annals of surgical oncology Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma. Abstract
Maehara, Yoshihiko	Kyushu University	11/13/2010	4.17	Annals of surgical oncology Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma. Abstract
Maehara, Yoshihiko	Kyushu University	04/22/2010	4.17	Annals of surgical oncology Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Abstract
Maehara, Yoshihko	Kyushu University	03/05/2010	4.17	Annals of surgical oncology Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Abstract
Maehara, Yoshihiko	Kyushu University	10/14/2009	4.17	Annals of surgical oncology Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Abstract
Chayama, Kazuaki	Hiroshima University	10/05/2012	4.16	Journal of gastroenterology Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. Abstract
Kumada, Hiromitsu	Toranomon Hospital	08/09/2012	4.16	Journal of gastroenterology Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. Abstract
Kumada, Hiromitsu	Toranomon Hospital	03/23/2012	4.16	Journal of gastroenterology Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. Abstract
Chayama, Kazuaki	Hiroshima University	02/18/2012	4.16	Journal of gastroenterology IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. Abstract
Chayama, Kazuaki	Hiroshima University	03/04/2011	4.16	Journal of gastroenterology Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. Abstract
Kumada, Hiromitsu	Toranomon Hospital	01/19/2011	4.16	Journal of gastroenterology Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. Abstract
Cheng, Ann-Lii	National Taiwan University Hospital	06/22/2010	4.16	Journal of gastroenterology Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	02/20/2013	4.15	Journal of clinical microbiology Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping. Abstract
Wedemeyer, Heiner	Hannover Medical School	03/29/2010	4.15	Journal of clinical microbiology Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	04/15/2009	4.15	Journal of clinical microbiology Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	12/21/2013	4.13	The Journal of infection Incidence and mortality of tuberculosis disease in Spain between 1997 and 2010: impact of human immunodeficiency virus (HIV) status. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	11/01/2013	4.13	The Journal of infection Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. Abstract
Pineda, Juan A	Hospital Universitario de Valme	03/28/2013	4.13	The Journal of infection Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. Abstract
Resino, Salvador	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	10/26/2012	4.13	The Journal of infection IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus. Abstract
Jemal, Ahmedin	Surveillance Research, American Cancer Society, Atlanta, GA	02/28/2011	4.12	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology Breast cancer incidence rates in U.S. women are no longer declining. Abstract
Couch, Fergus J	Mayo Clinic College of Medicine	05/19/2009	4.12	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. Abstract
	Sichuan University	03/31/2009	4.12	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Abstract
Buchholz, Thomas A	the University of Texas MD Anderson Cancer Center	08/15/2008	4.11	International journal of radiation oncology, biology, physics Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Abstract
Chayama, Kazuaki	Hiroshima University	12/20/2013	4.09	PloS one HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. Abstract
Dore, Gregory J	The University of New South Wales	11/20/2013	4.09	PloS one Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. Abstract
Lemon, Stanley M	The University of North Carolina at Chapel Hill	10/09/2013	4.09	PloS one microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. Abstract
Fan, Jia	Fudan University	09/13/2013	4.09	PloS one Promoting colonization in metastatic HCC cells by modulation of autophagy. Abstract
Kato, Nobuyuki	Okayama University Graduate School of Medicine	08/30/2013	4.09	PloS one New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication. Abstract
Wei, Lai	Peking University Hepatology Institute	06/24/2013	4.09	PloS one Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins. Abstract
Baumert, Thomas F	Inserm, U748, Strasbourg	05/21/2013	4.09	PloS one A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. Abstract
Fan, Jia	Fudan University	04/25/2013	4.09	PloS one Genetic polymorphism of the kinesin-like protein KIF1B gene and the risk of hepatocellular carcinoma. Abstract
Fan, Jia	Fudan University	02/28/2013	4.09	PloS one α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy. Abstract
He, Xiaoshun	Sun Yat-sen University	12/20/2012	4.09	PloS one Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. Abstract
He, Xianghuo	Fudan University	11/07/2012	4.09	PloS one MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. Abstract
Wei, Lixin	Second Military Medical University	08/28/2012	4.09	PloS one Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. Abstract
He, XiaoShun	Sun Yat-sen University	07/26/2012	4.09	PloS one Salvage liver transplantation for patients with recurrent hepatocellular carcinoma after curative resection. Abstract
Wei, Lai	Peking University Hepatology Institute	06/29/2012	4.09	PloS one Effects of interferon-alpha treatment on the incidence of hyperglycemia in chronic hepatitis C patients: a systematic review and meta-analysis. Abstract
Pietschmann, Thomas	Centre for Experimental and Clinical Infection Research	04/25/2012	4.09	PloS one Bile acids specifically increase hepatitis C virus RNA-replication. Abstract
Chung, Raymond T	Harvard Medical School	02/16/2012	4.09	PloS one ARF1 and GBF1 generate a PI4P-enriched environment supportive of hepatitis C virus replication. Abstract
Kato, Naoya	Shandong University	01/03/2012	4.09	PloS one ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. Abstract
Prins, Maria	University of California	11/15/2011	4.09	PloS one Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. Abstract
McKeating, Jane A	University of Birmingham	09/30/2011	4.09	PloS one Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. Abstract
Prins, Maria	University of California	09/14/2011	4.09	PloS one People with multiple tattoos and/or piercings are not at increased risk for HBV or HCV in The Netherlands. Abstract
Chayama, Kazuaki	Hiroshima University	08/23/2011	4.09	PloS one Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. Abstract
Ray, Ranjit	Saint Louis University	08/22/2011	4.09	PloS one A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. Abstract
Kato, Nobuyuki	Okayama University Graduate School of Medicine	01/11/2011	4.09	PloS one The ESCRT system is required for hepatitis C virus production. Abstract
Pawlotsky, Jean-Michel	Department of Virology, HÃ´pital Henri Mondor, UniversitÃ© Paris-Est CrÃ©teil	12/08/2009	4.09	PloS one Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. Abstract
Wedemeyer, H	Hannover Medical School	11/19/2013	4.09	Journal of viral hepatitis Hepatitis C virus core antigen testing in liver and kidney transplant recipients. Abstract
Zeuzem, S	Monash Medical Centre and Monash University	10/30/2013	4.09	Journal of viral hepatitis The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Abstract
Zeuzem, S	Monash Medical Centre and Monash University	06/21/2013	4.09	Journal of viral hepatitis Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. Abstract
Resino, S	Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid	12/20/2012	4.09	Journal of viral hepatitis IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. Abstract
Wei, L	Peking University Hepatology Institute	07/30/2012	4.09	Journal of viral hepatitis Association of suppressor of cytokine signalling 3 polymorphisms with insulin resistance in patients with chronic hepatitis C. Abstract
Kumada, H	Toranomon Hospital	07/13/2012	4.09	Journal of viral hepatitis Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. Abstract
McKeating, J A	University of Birmingham	04/13/2012	4.09	Journal of viral hepatitis Hepatitis C virus and the brain. Abstract
Zeuzem, S	Monash Medical Centre and Monash University	03/21/2012	4.09	Journal of viral hepatitis Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. Abstract
Cacoub, P	Laboratoire de Biologie et ThÃ©rapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C…	01/03/2012	4.09	Journal of viral hepatitis Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab. Abstract
Wedemeyer, H	Hannover Medical School	11/07/2011	4.09	Journal of viral hepatitis Immunosuppression, liver injury and post-transplant HCV recurrence. Abstract
Nguyen, M H	Stanford University Medical Center	10/07/2011	4.09	Journal of viral hepatitis Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients. Abstract
Chayama, K	Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima	09/14/2011	4.09	Journal of viral hepatitis Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection. Abstract
Wei, L	Peking University Hepatology Institute	08/04/2011	4.09	Journal of viral hepatitis IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. Abstract
Chayama, K	Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima	05/23/2011	4.09	Journal of viral hepatitis IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Abstract
Dore, G J	The University of New South Wales	02/17/2011	4.09	Journal of viral hepatitis Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007. Abstract
	Royal Derby Hospital	12/07/2010	4.09	Journal of viral hepatitis A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients.